About CLINUVEL

Dr Dennis Wright

BPharm MSc PhD

Acting Chief Scientific Officer

Dr Wright has a broad range of experience in the pharmaceutical industry spanning 25 years. He spent more than 17 years at CSL working predominantly in regulatory affairs with nearly a decade as Regulatory Affairs Manager.

During this time Dr Wright was responsible for the registration of a number of key products in Australia and the management of regulatory strategy for development projects.

Most recently he was Global Pharmacovigilance Manager and Regulatory Affairs Manager for the Australian and New Zealand operations of Mayne Pharma, a company recently acquired by Halcygen (ASX:HGN).

He has a Pharmacy degree and post-graduate qualifications from University of Sydney and Health Economics qualifications from Monash University, Melbourne. Dr Wright is responsible for leading the clinical and regulatory development team and progressing afamelanotide through to regulatory approval in global markets.

Latest Company Announcements

10 May 2017

Appendix 3B

Appendix 3B

Read More
10 May 2017

CLINUVEL Newsletter - May 2017

I look back at a turbulent period, as CLINUVEL has brought the ‘negotiations’ with GKV-Spitzenverband (National Association of Statutory Health Insurance Funds in Germany) to a successful end.

Read More
02 May 2017

NICE ENGLAND UPDATE ON SCENESSE®

CLINUVEL announce that the Department of Health has designated SCENESSE® to be evaluated as a Highly Specialised Technology (HST)

Read More
28 April 2017

Appendix 4C - Quarterly report

Appendix 4C

Read More
12 April 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
12 April 2017

CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board

CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board

Read More

Quick Links